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Abstract
Aim/hypothesis Underlying mechanisms for decreased cog-
nitive functioning in patients with type 2 diabetes are
unclear. In the general population, cerebral hypoperfusion
is a risk factor for cognitive dysfunction and dementia.
Reduced cerebral perfusion may account for cognitive
impairments in diabetic patients relative to controls.
Methods A total of 98 patients with type 2 diabetes and 47
control participants underwent neuropsychological evaluation.
Total cerebral blood flow (CBF) was assessed non-invasively
by measuring the volume flow in the internal carotid arteries
and basilar artery with two-dimensional phase–contrast
magnetic resonance angiography. Relative total CBF, a
measure of mean total cerebral perfusion, was obtained by
expressing total CBF per 100 ml brain parenchyma volume.
Results Patients with type 2 diabetes performed worse on
neuropsychological tests (p<0.05). Total CBF per 100 ml
brain parenchyma volume did not differ between partic-
ipants with and without diabetes (difference −2.3 ml min
−1
100 ml
−1; 95% CI −6.0, 1.3). In the entire group, total CBF
per 100 ml brain parenchyma volume was positively
associated with cognitive functioning (0.09 SD increase in
composite z score per 10 ml min
−1 100 ml
−1 increase in
relative total CBF). This association was not affected by
type 2 diabetes.
Conclusions/interpretation Although total CBF per 100 ml
brain parenchyma volume was associated with cognitive
functioning, it did not explain cognitive impairments in
patients with type 2 diabetes relative to controls.
Keywords Cerebralperfusion.Cognition.Magnetic
resonanceimaging.Type2diabetes
Abbreviations
BA basilar artery
CBF cerebral blood flow
2D-PC two-dimensional phase-contrast
FLAIR fluid-attenuated inversion recovery
ICAs internal carotid arteries
IR inversion recovery
MRA magnetic resonance angiography
MRI magnetic resonance imaging
PET positron emission tomography
SPECT single photon emission computed tomography
Introduction
Type 2 diabetes increases the risk of cognitive impairment
and vascular dementia [1]. In the general population,
cerebral hypoperfusion is a risk factor for cognitive
dysfunction and dementia [2–4]. Therefore, differences in
cerebral perfusion between patients with and without
diabetes might explain their differences in cognitive function.
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type 2 diabetes are scarce. Reductions up to 30% in several
brain regions [5, 6] and a lower overall cerebral perfusion
[6] have been observed in single photon emission computed
tomography(SPECT)orpositronemissiontomography(PET)
studies. A recent study using non-invasive arterial spin
labelling magnetic resonance imaging (MRI) did not find an
effect of type 2 diabetes on regional cerebral perfusion [7].
Small sample sizes and potential selection bias may explain
part of the variation between these studies.
Additional information on the effect of cerebral perfu-
sion on mild cognitive dysfunction in diabetic patients may
be obtained from studies in patients with type 1 diabetes
mellitus, as many of the underlying mechanisms may be
common to both forms of diabetes. Indeed, cerebral hypo-
perfusion has been described in children and adults with
type 1 diabetes mellitus [8–11], but not consistently [12],
and its role in the development of cognitive decrements has
not been established [11].
Two-dimensional phase-contrast (2D-PC) magnetic res-
onance angiography (MRA) is a non-invasive, accurate
method for measuring total cerebral blood flow (total CBF)
[13–15], and is therefore applicable for use in large groups
of healthy participants. Relative total CBF, a measure of
mean total cerebral perfusion, is obtained by dividing total
CBF by brain volume [16].
Until now, the relation between cerebral perfusion,
cognitive functioning and type 2 diabetes has not been
investigated in the same study population. The aim of the
current study was to investigate whether cerebral perfusion,
as measured non-invasively with 2D-PC MRAvolume flow
quantification, differs between participants with and with-
out type 2 diabetes and whether this could account for the
decrease in cognitive functioning of patients with type 2
diabetes relative to controls.
Methods
Participants
We included participants of the Utrecht Diabetic Encepha-
lopathy Study (UDES), a cross-sectional population-based
study on determinants of impaired cognition in patients with
type2diabetes.Dataoncognitionandbrainimagingfindings
from this study have been reported previously [17]. Between
September 2002 and November 2004, patients with type 2
diabetes were recruited through their general practitioner
and control participants of at least 56 years were recruited
from among the spouses or acquaintances of the patients.
Therefore, patients were not selected for the presence or
absence of diabetic complications or co-morbid conditions
(e.g. hypertension). For inclusion, type 2 diabetic patients
had to be 55 to 80 years of age, have a disease duration of
at least 1 year, be functionally independent and speak
Dutch. Exclusion criteria for all participants included a
psychiatric or neurological disorder (unrelated to diabetes)
that could influence cognitive functioning, history of alcohol
or substance abuse, or history of dementia. For control
participants, exclusion criteria additionally included fasting
blood glucose ≥7.0 mmol/l. Participants with a history of
non-incapacitating stroke were included. Approval for the
study was obtained from the medical ethics committee of the
University Medical Center Utrecht, the Netherlands, and
written, informed consent was provided by all participants.
For the present study, we excluded participants for whom
MRI of the brain was not available due to MRI contra-
indications(n=15) and missing (n=8 )o ri r r e t r i e v a b l e( n=10)
digital MRI records. Hence, analyses were performed in 145
participants (98 patients with type 2 diabetes and 47 controls).
Participant characteristics
Information about the presence of vascular risk factors was
assessed by means of a standardised interview and by
physical and laboratory examinations. Blood pressure was
measured at nine fixed time points during the day with an
automatic blood pressure device (705CP; Omron, Hamburg,
Germany). Hypertension was defined as a mean systolic
blood pressure above 160 mmHg, a mean diastolic pressure
above 95 mmHg or the use of antihypertensive medication.
FastingglucoseandHbA1c levels were determined by means
of a venous blood sample. The presence of macrovascular
disease was defined as a history of myocardial infarction,
stroke, vascular surgery or endovascular treatment for
coronary, carotid or peripheral artery disease.
Magnetic resonance imaging
Brain MRI was performed on a 1.5 T scanner (Philips
Medical Systems, Best, the Netherlands). The protocol
consisted of axial T1 weighted (repetition time [TR]
234 ms/echo time [TE] 2 ms), inversion recovery (IR; TR
2,900 ms/TE 22 ms) and FLAIR (TR 6,000 ms/inversion
time [TI] 2,000 ms/TE 100 ms) scans, performed with
4 mm slice thickness, no slice gap and 38 slices, covering
the entire brain, with a field of view of 230×230 mm and a
256×256 scan matrix.
On the basis of two magnetic resonance (MR) localiser
scans in the coronal and sagittal plane, a 2D-PC MR section
was positioned at the level of the skull base to measure the
volume flow in the internal carotid arteries (ICAs) and
basilar artery (BA; TR 16 ms; TE 9 ms; flip angle 7.5°; field
of view 250×250 mm; matrix 256×256; section thickness
5 mm; averages 8; velocity sensitivity 100 cm/s; Fig. 1)[ 15].
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Assessment of brain volume Volumetric assessment of brain
parenchyma volume was performed using an automated
probabilisticsegmentationmethod,whichhasbeendescribed
previously [18]. In short, the algorithm is based on infor-
mation from the T1-w, IR and FLAIR images. It uses the
K-Nearest Neighbour classification technique that is based
on both spatial information and voxel intensities. For each
voxel the algorithm determines the probability that it is part
of a specific brain tissue type. Segmentation and volumes of
five different brain tissue types (grey matter, white matter,
pericerebral cerebrospinal fluid, ventricles and white matter
lesions) are calculated automatically.
Total brain volume was defined as the sum of the
volumes of grey and white matter and white matter lesions.
Measurement of total cerebral blood flow and assessment
of relative total brain perfusion Regions of interest were
manually drawn closely around the vessel lumens of both
ICAs and the BA on the phase–difference images (Fig. 1)
and flow velocities were multiplied by the cross-sectional
area of the pixels in the region of interest to obtain volume
flow rates (in ml/s) [13–15]. The flow through the three
vessels was then summed and multiplied by 60 s/min to
calculate the total CBF (in ml/min).
Because total CBF is influenced by brain size, we
calculated mean total cerebral perfusion (total CBF relative
to a participant’s brain volume) by dividing total CBF (in
ml/min) by brain volume (in ml) and multiplying by 100,
thus obtaining a measure in ml/min per 100 ml brain tissue
[16, 19].
Neuropsychological tests
All participants underwent an extensive neuropsychological
evaluation, including 11 different tests addressing five cog-
nitive domains: visuo-construction, attention and executive
function, information processing speed, memory and abstract
reasoning.PremorbidIQwastestedwiththeDutchversionof
the National Adult Reading Test [20] and educational level
was recorded in seven categories and transferred to years of
education [21]. These tasks took about 90 min to complete.
Summary scores for the five cognitive domains were con-
structed by converting the raw scores from the individual
tests to standardised scores (z scores) that were based on
the means and pooled standard deviations of the whole
Table 1 Characteristics of the participants
With type 2
diabetes (n=98)
Without type 2
diabetes (n=47)
Demographic factors
Age (years) 66.0 (5.7) 64.9 (5.4)
Sex (men)
a 50 (51) 20 (43)
Level of education
b 4( 3 –5) 4 (3–5)
Estimated premorbid IQ 98.7 (15.8) 100.6 (14.3)
Vascular risk factors
BMI (kg/m
2) 28.2 (4.3) 27.3 (5.1)
Systolic blood pressure (mmHg) 147.3 (19.9) 138.7 (19.2)
Diastolic blood pressure (mmHg) 81.9 (9.6) 78.5 (8.7)
Hypertension
a 79 (81) 16 (34)
History of stroke
a 6 (6) 0 (0)
History of any vascular disease
a 26 (27) 2 (4)
Diabetes-related factors
Fasting serum glucose (mmol/l) 8.7 (3.1) 5.5 (0.6)
Total diabetes duration (years) 8.6 (6.1) NA
HbA1c (%) 6.9 (1.3) 5.5 (0.3)
Insulin treatment
a 28 (29) 0
Global cognitive performance
Composite z score −0.07 (0.06) 0.14 (0.06)
Brain MRI measures
Lacunar infarcts
a 9 (9) 3 (6)
Large infarcts
a 6 (6) 1 (2)
White matter lesion volume (ml) 2.8 (1.2–5.0) 1.9 (0.9–3.6)
Brain volume (ml) 1,076.2 (103.1) 1,106.7 (87.5)
Data shown are means (SD or SE for z score), medians (IQR) or
aproportions (%)
bSeven categories, corresponding to years of education as follows: <6,
6–7, 8, 9, 10–11, 12–18 and >18
NA, not applicable
Fig. 1 Sagittal localiser magnetic resonance angiogram illustrating
the positioning of a two-dimensional phase-contrast MR section to
measure the volume flow through the internal carotid arteries and
basilar artery. Quantitative magnetic resonance flow values were
obtained by integrating across manually drawn regions that enclose
the vessels. 1, right ICA; 2, left ICA; 3, basilar artery
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the same cognitive domain were averaged. By averaging the
z scores of the five domains a composite z score was cal-
culated as a measure of global cognitive functioning.
Statistical analysis
Differences in neuropsychological performance and MR
variables between type 2 diabetic patients and controls were
analysed with multivariable linear regression adjusted for
age, sex and estimated IQ.
Linear regression analyses with adjustment for age, sex
and IQ were also performed to assess the relationship of
diabetes and other vascular risk factors with relative total
CBF and to investigate the association of relative total CBF
with cognitive function.
Results
The baseline characteristics of the participants are outlined
in Table 1. Patients with type 2 diabetes performed worse
on neuropsychological tests and had smaller brain volumes
than control participants without type 2 diabetes (p<0.05
for both, adjusted for age, sex and IQ; Table 1).
Mean relative total CBF in the entire study population
was 51.9 ml/min per 100 ml brain tissue, which, divided
by brain tissue density (1.034 g/ml) [19], corresponds to
50.2 ml/min per 100 g brain tissue. Total CBF (uncorrected
for brain volume) was lower in participants with than in
those without type 2 diabetes (difference −46.6 ml/min;
95% CI −88.6, −4.6). However, relative total CBF (total
CBF per 100 ml brain parenchyma volume) was not
significantly different in patients with type 2 diabetes
compared with those without (difference −2.3 ml min
−1
100 ml
−1; 95% CI −6.0, 1.3; Table 2).
Hypertension (CBF −5.0 ml min
−1 100 ml
−1;9 5 %C I−8.6,
−1.4) and diastolic blood pressure (CBF −2.1 ml min
−1
100 ml
−1; 95% CI −3.9, −0.3 per 10 mmHg elevation) were
significantly associated with relative total CBF (Table 2).
We found no interaction between hypertension or blood
pressure and type 2 diabetes. No other diabetes-related
factors or vascular risk factors were associated with relative
total CBF (Table 2).
Across the whole population, relative total CBF was
positively associated with information processing speed,
attention and executive function, visuoconstruction and
global cognitive performance (Table 3), with a 0.09 SD
increase in composite z score per 10 ml min
−1 100 ml
−1
increase in relative total CBF; 95% CI 0.03, 0.15. Adjust-
ment forhypertension,white matterlesionsandlargeinfarcts
on MRI did not change this association. Moreover, exclusion
of patients with large infarcts on MRI (n=6) did not affect
the results (data not shown). There was also a positive
relationship between relative total CBF and cognitive
functioning within the diabetic group alone (Table 3).
Table 3 Relation between relative total CBF (10 ml min
−1 100 ml
−1) and cognitive function
Information
processing speed
a
Attention and
executive function
a
Memory
a Abstract
reasoning
a
Visuo-
construction
a
Global cognitive
performance
a
Relative total CBF
b
All participants 0.14* (0.02, 0.26) 0.11** (0.03, 0.19) −0.02 (−0.09, 0.05) 0.08 (−0.05, 0.21) 0.16* (0.02, 0.30) 0.09** (0.03, 0.15)
Type 2 diabetic
patients
0.16 (−0.01, 0.32) 0.13* (0.01, 0.24) −0.03 (−0.13, 0.06) 0.18 (−0.01, 0.37) 0.21* (0.02, 0.40) 0.12** (0.03, 0.21)
Linear regression analysis with regression coefficients B (95% CI), adjusted for age, sex and IQ
az score
b10 ml min
−1 100 ml
−1
*p<0.05, **p<0.01
Table 2 Relation of type 2
diabetes and other (vascular)
risk factors with relative total
CBF
Linear regression analysis,
adjusted for age and sex
*p<0.05
Relative total CBF (ml min
−1 100 ml
−1)
Regression coefficient B 95% CI
Diabetes (yes/no) −2.3 −6.0, 1.3
Glucose (mmol/l) −0.3 −0.9, 0.4
HbA1c (%) −0.8 −2.2, 0.6
Hypertension (yes/no) −5.0 −8.6, −1.4*
Diastolic BP (per 10 mmHg elevation) −2.1 −3.9, −0.3*
Systolic BP (per 10 mmHg elevation) −0.01 −0.9, 0.9
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We were interested in determining the relation between
type 2 diabetes and cerebral perfusion to identify underlying
vascular mechanisms and to clarify the pathogenesis of
impaired cognitive functioning and increased risk of demen-
tia in type 2 diabetes. We have shown that relative total CBF,
expressed in ml/min per 100 ml brain tissue, was positively
related to cognitive functioning, but that this relation was
independent of type 2 diabetes. Differences in cognitive
functioning between participants with and without type 2
diabetescouldthereforenotbeattributedtodifferencesintotal
cerebral perfusion. Total CBF, cerebral perfusion and brain
volume can all change as a consequence of type 2 diabetes,
but apparently these changes can occur independently.
Thus far, the few studies on cerebral perfusion in type 2
diabetes measured regional CBF with SPECT or PET and
included only a small number of patients (27 and 16 patients,
respectively) or were performed in patients with severe
diabetic complications (e.g. symptomatic cerebral micro-
angiopathy) [5, 6]. A lower regional CBF in all regions of
the cortex [5, 6] and a lower overall CBF [6] in the diabetic
group than in the non-diabetic group have been reported.
Based on these findings, we hypothesised that total cerebral
hypoperfusion might explain cognitive dysfunction in our
patients with type 2 diabetes. However, the methodological
issues mentioned above may explain the lack of consistency
with previous findings.
Differences in total CBF between individuals can, among
others, be attributed to differences in brain size [16, 19].
Quantitative flow measurements in the ICAs and BA by
2D-PC MRA, expressed per 100 ml brain volume, provide
mean total cerebral perfusion values that are comparable to
normal values of cerebral perfusion measured by other
imaging techniques (50.0 ml min
−1 100 g
−1)[ 22]. Patients
with type 2 diabetes are prone to a modest degree of brain
atrophy [23]. This explains the difference in total CBF
between patients with and without type 2 diabetes and the
lack of a significant difference in mean total cerebral
perfusion (relative total CBF). In a study of patients with
symptomatic arterial disease, diabetes was also associated
with a lower total CBF (β −42.0 ml/min, comparable with
our results), but correction for brain volume was not per-
formed [24]. The authors stated that adjustment for age
could have accounted for the effect of brain atrophy, but
this remains an assumption. Sabri et al. [6] also observed
that the effect of type 2 diabetes on regional CBF might be
confounded by concomitant brain atrophy, which was
measured with a relatively crude visual ordinal rating scale.
Noprevious studies have demonstrated a relation between
reduced relative total CBF and mild cognitive impairment
using 2D-PC MRA flow measurements through the ICAs
and BA. Only one previous study found a lower total CBF
in patients with dementia, but the investigators did not
correct for brain volume, although patients with dementia
had significantly more brain atrophy [25].
We show that impaired cognitive functioning in patients
with type 2 diabetes relative to controls is not attributable
to the relative total CBF under resting conditions. Never-
theless, it is possible that cerebrovascular reactivity, the
vasodilatory response to a vascular challenge, is impaired in
patients with type 2 diabetes. Conceivably, such an impaired
vascular reactivity could have an effect on the relation
between type 2 diabetes and cognitive dysfunction.
From our findings we cannot exclude that more focal
areas with hypoperfusion were present in our population of
patientswithtype2diabetes,ashasbeenobservedpreviously,
especially in patients with type 1 diabetes mellitus [8–11].
However, these focal changes in hypoperfusion do not seem
to affect the overall perfusion of the brain. A difference
between these previous studies and ours is that we corrected
for brain volume in the present study based on MR seg-
mentation of the brain parenchyma. Without correction for
brain volume, cerebral perfusion may be underestimated in
patients with diabetes mellitus relative to controls, due to
increased atrophy in the former compared with controls.
In this cross-sectional study we combined data on cerebral
perfusion,type 2diabetesandcognitive function.We showed
that reduced total cerebral perfusion was associated with
impaired cognitive functioning. It is as yet unclear whether
cerebral hypoperfusion is the cause (i.e. through moderate
ischaemia) or theconsequence (i.e. through reduceddemand)
of impaired cognition. In any case, the effect of type 2
diabetes mellitus on cognitive performance in our population
could not be explained by a reduced total cerebral perfusion.
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